Fiona C. Crawford, PhD
Research Biologist
Fiona.Crawford@va.gov
Fcrawford@roskampinstitute.org
Affiliation(s)
The Roskamp Institute
Chief Executive Officer
Research
Research Area(s): Traumatic brain injury; Alzheimer’s Disease and related dementias; Post-traumatic Stress Disorder; Gulf War Illness
Research Population: Patients suffering from the effects of traumatic brain injury; Alzheimer’s Disease and Dementia patients; Patients suffering from Post-traumatic Stress Disorder; Patients with Gulf War Illness
Research Methods: Development and characterization of translationally relevant preclinical models of diseases/disorders; Behavioral testing, Immunohistochemistry, Molecular Neuroscience; Mass spectrometry – proteomics, lipidomics, metabolomics; Antibody based approaches – ELISA, Immunoblotting
Collaboration
Dr. Crawford is Interested in collaborating with anyone who has access to relevant patient populations in order to harness both basic and clinical research to develop diagnostic and theragnostic biomarkers and validate therapeutic strategies.
Connect with Dr. Crawford
Recent Funding History
| Dates | Title | Funding Source and Type | Role |
|---|---|---|---|
| 2024 – 2028 | PDE2a inhibition as a therapeutic target for the chronic effects of repetitive mild TBI | VA RRD | PI |
| 2024 – 2026 | Identification of genes conferring susceptibility in a preclinical model of PTSD | VA SPiRE | PI |
| 2024 – 2028 | Targeting APOE bioenergetics for reducing the risk of neurodegeneration after chronic traumatic brain injury | DoD CDMRP | Co-I |
| 2024 – 2028 | Development of ultra-selective DYRK1A inhibitors as a novel therapeutic modality for TBI | DoD CDMRP | Co-I |
| 2024 – 2026 | Aberrant PTEN signaling in chronically activated microglia drives tau pathology, neurodegeneration and cognitive decline following repetitive brain injury | NIH NINDS | Co-I |
| 2023 – 2026 | Microglial NOX2/NLRP3 inflammasome activation drives tau pathology and cognitive impairments in chronic traumatic brain injury | DoD CDMRP | Co-I |